<?xml version="1.0" encoding="utf-8"?>
<rr:ResultsReport>
	<rr:ResultsPayload>
		<FinalReport>
			<Sample>
				<FM_Id>AA -24-00392</FM_Id>
				<SampleId></SampleId>
				<BlockId>M113-10021_(PT24004)</BlockId>
				<TRFNumber></TRFNumber>
				<TestType></TestType>
				<SpecFormat>Bone  Type</SpecFormat>
				<ReceivedDate>Jan 18, 2024</ReceivedDate>
			</Sample>
			<PMI>
				<ReportId></ReportId>
				<MRN>***79121</MRN>
				<FullName>黃*源</FullName>
				<FirstName></FirstName>
				<LastName></LastName>
				<SubmittedDiagnosis>Metastatic adenocarcinoma</SubmittedDiagnosis>
				<Gender>Male</Gender>
				<DOB>Nov **, 1956</DOB>
				<OrderingMD>陳天華醫師</OrderingMD>
				<OrderingMDId></OrderingMDId>
				<Pathologist></Pathologist>
				<CopiedPhysician1></CopiedPhysician1>
				<MedFacilName>臺北榮總</MedFacilName>
				<MedFacilID></MedFacilID>
				<SpecSite></SpecSite>
				<CollDate></CollDate>
				<ReceivedDate></ReceivedDate>
				<CountryOfOrigin></CountryOfOrigin>
			</PMI>
		</FinalReport>
		<variant-report>
			<short_variants>
				<short_variant>
					<cds_effect>c.1862C&gt;T</cds_effect>
					<depth>1193</depth>
					<gene>CSF1R</gene>
					<percent_reads>54.2%</percent_reads>
					<protein_effect>T621M</protein_effect>
					<transcript>NM_005211</transcript>
				</short_variant>
				<short_variant>
					<cds_effect>c.6683C&gt;T</cds_effect>
					<depth>619</depth>
					<gene>FAT1</gene>
					<percent_reads>15.3%</percent_reads>
					<protein_effect>T2228I</protein_effect>
					<transcript>NM_005245</transcript>
				</short_variant>
				<short_variant>
					<cds_effect>c.1513G&gt;A</cds_effect>
					<depth>663</depth>
					<gene>FGFR3</gene>
					<percent_reads>82.1%</percent_reads>
					<protein_effect>V505I</protein_effect>
					<transcript>NM_000142</transcript>
				</short_variant>
				<short_variant>
					<cds_effect>c.2566C&gt;G</cds_effect>
					<depth>2129</depth>
					<gene>GRIN2A</gene>
					<percent_reads>58.2%</percent_reads>
					<protein_effect>R856G</protein_effect>
					<transcript>NM_000833</transcript>
				</short_variant>
				<short_variant>
					<cds_effect>c.6283C&gt;T</cds_effect>
					<depth>1430</depth>
					<gene>NOTCH1</gene>
					<percent_reads>45.5%</percent_reads>
					<protein_effect>R2095C</protein_effect>
					<transcript>NM_017617</transcript>
				</short_variant>
				<short_variant>
					<cds_effect>-</cds_effect>
					<depth>-</depth>
					<gene>POLD1</gene>
					<percent_reads>NM_001256849</percent_reads>
					<protein_effect>Splice</protein_effect>
					<transcript>c.1893</transcript>
				</short_variant>
				<short_variant>
					<cds_effect>15</cds_effect>
					<depth>98.2%</depth>
					<gene>RBM10</gene>
					<percent_reads>-</percent_reads>
					<protein_effect>Splice</protein_effect>
					<transcript>c.1692C&gt;T</transcript>
				</short_variant>
				<short_variant>
					<cds_effect>c.16901T&gt;C</cds_effect>
					<depth>32</depth>
					<gene>SYNE1</gene>
					<percent_reads>21.6%</percent_reads>
					<protein_effect>M5634T</protein_effect>
					<transcript>NM_182961</transcript>
				</short_variant>
			</short_variants>
			<copy_number_alterations>
				<copy_number_alteration>
					<copy_number>1</copy_number>
					<gene>CDKN2A</gene>
					<position>Chr9</position>
					<type>Heterozygous deletion</type>
				</copy_number_alteration>
			</copy_number_alterations>
			<rearrangements>
			</rearrangements>
			<biomarkers>
				<microsatellite_instability>
					<status>Microsatellite stable (MSS)</status>
				</microsatellite_instability>
				<tumor_mutation_burden>
					<score>0.0</score>
				</tumor_mutation_burden>
			</biomarkers>
		</variant-report>
	</rr:ResultsPayload>
</rr:ResultsReport>